New Data Presented at the 28th ECTRIMS Congress Showcase Teva’s Ongoing Commitment to Multiple Sclerosis Research

JERUSALEM--(BUSINESS WIRE)--

Teva Pharmaceutical Industries Ltd. (TEVA) today announced that key data from the Companys multiple sclerosis (MS) franchise will be featured at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13, 2012. Data presentations will provide new insights on COPAXONE (glatiramer acetate injection), the worlds leading relapsing-remitting multiple sclerosis (RRMS) treatment, and Tevas investigational oral compound laquinimod, as well as results from the ongoing TOP MS and NARCOMS studies.

"For more than 20, years Teva has been at the forefront of MS research and development focused on providing effective and safe treatments aimed at meeting the needs of patients living with this complex, often debilitating disease, said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer for Teva Pharmaceutical Industries Ltd. The data being presented at ECTRIMS demonstrate our ongoing commitment to enhancing the treatment experience for RRMS patients and advancing science to assist neurologists in making appropriate treatment decisions, especially as the market continues to evolve.

In addition to the data being presented at the Congress, Teva will host a satellite symposium, New Concepts in MS Pathology Shed Light on MS Treatment Approaches on Thursday, October 11, 2012 from 19:15 - 20:15 CET. Teva will also host a media event for credentialed journalists on Thursday, October 11, 2012 at 12:00 CET focused on advancements made in RRMS and future considerations for treatment.

Teva-Sponsored Data Highlights Include:

Glatiramer Acetate:

The multinational randomized, double-blind placebo-controlled Phase III Glatiramer Acetate Low-frequency Administration (GALA) study examined the efficacy, safety and tolerability of an investigational formulation of glatiramer acetate 40 mg/1 ml administered three times a week compared to placebo in a randomized, double-blind placebo-controlled design in patients with RRMS. A late-breaking news parallel session will present detailed clinical data on October 13, 2012, while a poster presentation will analyze baseline patient demographics for this trial. Key posters include:

Laquinimod:

Laquinimod is an oral, once-daily investigational central nervous system (CNS)-active immunomodulator with a novel mechanism of action in development for the treatment of RRMS. Multiple presentations at ECTRIMS further demonstrate the clinical benefits of this unique compound. Ongoing analyses from the open-label extension phase of the ALLEGRO trial assessing the effect on disease course in patients treated with laquinimod for three years, as well as in patients originally treated with placebo and switched to laquinimod treatment for one year, may provide further possible evidence surrounding the effectiveness of the compound in decreasing relapse rates. Further analyses on other clinical endpoints such as disability and safety will be discussed. Results from an additional study using several magnetic resonance imaging (MRI) techniques sensitive to irreversible tissue damage such as measurements of brain volume or magnetic transfer ratio (MTR) were consistent with the positive impact on disability progression demonstrated with the therapy. Key posters include:

Multiple Sclerosis:

Excerpt from:
New Data Presented at the 28th ECTRIMS Congress Showcase Teva’s Ongoing Commitment to Multiple Sclerosis Research